platinum-doublet + bevacizumab

A combination chemotherapy and targeted therapy regimen consisting of a platinum-based doublet (typically carboplatin or cisplatin paired with a second agent like paclitaxel, gemcitabine, or pegylated liposomal doxorubicin) and the anti-angiogenic monoclonal antibody bevacizumab. This regimen is a standard-of-care treatment for advanced or recurrent ovarian, fallopian tube, and primary peritoneal cancers. The platinum component induces DNA damage and inhibits replication, while bevacizumab binds to vascular endothelial growth factor (VEGF), preventing its interaction with receptors on the surface of endothelial cells, thereby inhibiting tumor angiogenesis. In clinical trials such as the Phase 3 OnPrime (GOG-3076) study, this combination serves as both a standard-of-care comparator and a backbone for experimental therapies like Olvi-Vec.

Other names

platinum-based chemotherapy + bevacizumabplatinum-based doublet + bevacizumab